These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8056999)

  • 21. Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation.
    Blier P; Seletti B; Gilbert F; Young SN; Benkelfat C
    Neuropsychopharmacology; 2002 Aug; 27(2):301-8. PubMed ID: 12093604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA; L'Heureux F; Hill JL; Bihari K; Bernstein SE; Murphy DL
    J Clin Psychopharmacol; 1992 Feb; 12(1):11-8. PubMed ID: 1552034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.
    Lesch KP; Hoh A; Schulte HM; Osterheider M; Müller T
    Psychopharmacology (Berl); 1991; 105(3):415-20. PubMed ID: 1686817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls.
    Lesch KP; Hoh A; Disselkamp-Tietze J; Wiesmann M; Osterheider M; Schulte HM
    Arch Gen Psychiatry; 1991 Jun; 48(6):540-7. PubMed ID: 1674853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased prolactin response to buspirone in chronic fatigue syndrome.
    Sharpe M; Clements A; Hawton K; Young AH; Sargent P; Cowen PJ
    J Affect Disord; 1996 Nov; 41(1):71-6. PubMed ID: 8938208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
    Grady TA; Pigott TA; L'Heureux F; Hill JL; Bernstein SE; Murphy DL
    Am J Psychiatry; 1993 May; 150(5):819-21. PubMed ID: 8480832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation with buspirone: a review.
    Harvey KV; Balon R
    Ann Clin Psychiatry; 1995 Sep; 7(3):143-7. PubMed ID: 8646275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone.
    Cowen PJ; Power AC; Ware CJ; Anderson IM
    Br J Psychiatry; 1994 Mar; 164(3):372-9. PubMed ID: 8199791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder.
    Fineberg NA; Cowen PJ; Kirk JW; Montgomery SA
    J Affect Disord; 1994 Oct; 32(2):97-104. PubMed ID: 7829769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine.
    Fineberg NA; Roberts A; Montgomery SA; Cowen PJ
    Br J Psychiatry; 1997 Sep; 171():280-2. PubMed ID: 9337985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
    Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buspirone challenge: preliminary evidence for a role for central 5-HT1a receptor function in impulsive aggressive behavior in humans.
    Coccaro EF; Gabriel S; Siever LJ
    Psychopharmacol Bull; 1990; 26(3):393-405. PubMed ID: 2274641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects.
    Schwartz PJ; Turner EH; Garcia-Borreguero D; Sedway J; Vetticad RG; Wehr TA; Murphy DL; Rosenthal NE
    Psychiatry Res; 1999 Apr; 86(1):9-28. PubMed ID: 10359479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
    Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
    Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buspirone and fluoxetine in the treatment of OCD.
    Judd F; Ellen S; Norman T
    Aust N Z J Psychiatry; 1992 Dec; 26(4):684-6. PubMed ID: 1476539
    [No Abstract]   [Full Text] [Related]  

  • 38. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
    Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.